tailieunhanh - A novel circular RNA hsa_circRNA_103809/ miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC)

Cisplatin is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and emerging evidences suggests that targeting circular RNAs (circRNAs) is an effective strategy to increase cisplatin-sensitivity in NSCLC, but the detailed mechanisms are still not fully delineated. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN